US Maps Strategy to Reform Drug Pricing
After months of threats and promises, President Donald Trump finally unveiled his strategy for realizing more affordable prescription medicines in the US. Trump pledged to take on the “tangled web of special interests” that drive up drug prices and chided supply chain middlemen for getting “very rich” under the current system.
The lack of specifics, though, produced a general shrug from industry and the investment community and
Jill Wechsler
visible disappointment from public health activists. The administration’s “American Patients First” blueprint, unveiled at a May 11 Rose Garden speech, blasts “global freeloading” by industrial nations and proposes major changes in Medicare and Medicaid drug coverage policies, but stops short of authorizing the federal government to directly negotiate Medicare drug prices and or to permit “safe” importation of prescription drugs from other countries, as sought by Democrats and consumer advocates.
Read more: http://www.pharmexec.com/us-maps-strategy-reform-drug-pricing
The lack of specifics, though, produced a general shrug from industry and the investment community and
Jill Wechsler
visible disappointment from public health activists. The administration’s “American Patients First” blueprint, unveiled at a May 11 Rose Garden speech, blasts “global freeloading” by industrial nations and proposes major changes in Medicare and Medicaid drug coverage policies, but stops short of authorizing the federal government to directly negotiate Medicare drug prices and or to permit “safe” importation of prescription drugs from other countries, as sought by Democrats and consumer advocates.
Read more: http://www.pharmexec.com/us-maps-strategy-reform-drug-pricing